Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance

威尼斯人 癌症研究 慢性淋巴细胞白血病 白血病 Bcl-2家族 癌变 淋巴瘤 髓样 生物 细胞凋亡 医学 免疫学 癌症 程序性细胞死亡 遗传学
作者
Isha Kapoor,Juraj Bodo,Brian Thomas Hill,Eric D. Hsi,Alexandru Almasan
出处
期刊:Cell Death and Disease [Springer Nature]
卷期号:11 (11): 941-941 被引量:250
标识
DOI:10.1038/s41419-020-03144-y
摘要

Defects in apoptosis can promote tumorigenesis and impair responses of malignant B cells to chemotherapeutics. Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of proteins are key regulators of the intrinsic, mitochondrial apoptotic pathway. Overexpression of antiapoptotic BCL-2 family proteins is associated with treatment resistance and poor prognosis. Thus, inhibition of BCL-2 family proteins is a rational therapeutic option for malignancies that are dependent on antiapoptotic BCL-2 family proteins. Venetoclax (ABT-199, GDC-0199) is a highly selective BCL-2 inhibitor that represents the first approved agent of this class and is currently widely used in the treatment of chronic lymphocytic leukemia (CLL) as well as acute myeloid leukemia (AML). Despite impressive clinical activity, venetoclax monotherapy for a prolonged duration can lead to drug resistance or loss of dependence on the targeted protein. In this review, we provide an overview of the mechanism of action of BCL-2 inhibition and the role of this approach in the current treatment paradigm of B-cell malignancies. We summarize the drivers of de novo and acquired resistance to venetoclax that are closely associated with complex clonal shifts, interplay of expression and interactions of BCL-2 family members, transcriptional regulators, and metabolic modulators. We also examine how tumors initially resistant to venetoclax become responsive to it following prior therapies. Here, we summarize preclinical data providing a rationale for efficacious combination strategies of venetoclax to overcome therapeutic resistance by a targeted approach directed against alternative antiapoptotic BCL-2 family proteins (MCL-1, BCL-xL), compensatory prosurvival pathways, epigenetic modifiers, and dysregulated cellular metabolism/energetics for durable clinical remissions.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
zz完成签到,获得积分10
1秒前
duck发布了新的文献求助10
1秒前
1秒前
黑米粥发布了新的文献求助200
2秒前
ding的应助被汤汤采纳,获得10
2秒前
王明磊完成签到 ,获得积分10
2秒前
白辉发布了新的文献求助10
2秒前
3秒前
3秒前
3秒前
滕靖完成签到,获得积分10
3秒前
5秒前
wanwusheng完成签到,获得积分10
5秒前
852的应助被周依依采纳,获得10
6秒前
zhscu完成签到,获得积分10
6秒前
无极微光的应助被ZZ_star采纳,获得20
6秒前
7秒前
花未稀发布了新的文献求助10
7秒前
7秒前
8秒前
旦斯特尼发布了新的文献求助10
8秒前
Joseph0209发布了新的文献求助10
8秒前
小马甲的应助被吱吱采纳,获得10
8秒前
Changhiwi完成签到 ,获得积分10
9秒前
rd_z完成签到,获得积分10
9秒前
9秒前
在游的客完成签到,获得积分10
9秒前
9秒前
9秒前
guo发布了新的文献求助10
10秒前
不开花花发布了新的文献求助10
12秒前
情怀的应助被e00ec采纳,获得10
12秒前
12秒前
12秒前
苗条梨愁发布了新的文献求助10
13秒前
yy发布了新的文献求助10
13秒前
duck完成签到,获得积分10
14秒前
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183792
求助须知:如何正确求助?哪些是违规求助? 9573020
关于积分的说明 21828776
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434116
关于科研通互助平台的介绍 2558301
邀请新用户注册赠送积分活动 2480611